Dabigatran versus warfarin in patients with atrial fibrillation

Cited by (1,022)

Items 401–500 of 1,022

1. Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism
   Bengt I. Eriksson, Daniel J. Quinlan, John W. Eikelboom · 2010 · Annual Review of Medicine
2. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial
   Sana M. Al‐Khatib, Laine Elliott Thomas, Lars C. Wallentin, Renato D. Lópes, Bernard John Gersh, David A. Garcia, Justin Adrian Ezekowitz, Marco Alings, Hongqui Yang, John Hunter Alexander et al. · 2013 · European Heart Journal
3. Rate control in atrial fibrillation
   Isabelle C. Van Gelder, Michiel Rienstra, Harry J.G.M. Crijns, Brian Olshansky · 2016 · The Lancet
4. Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies
   Jay Desai, Jennifer M. Kolb, Jeffrey Ian Weitz, James Aisenberg · 2013 · Thrombosis and Haemostasis
5. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
   Chern‐En Chiang, Ken Okumura, Shu Zhang, Tze‐Fan Chao, Chung‐Wah Siu, Toon Wei Lim, Anil Saxena, Yoshihide Takahashi, Wee Siong Teo · 2017 · Journal of Arrhythmia
6. Meta-analysis: Effect of Patient Self-testing and Self-management of Long-Term Anticoagulation on Major Clinical Outcomes
   Hanna E. Bloomfield, Ange Krause, Nancy L. Greer, Brent C Taylor, Roderick H. MacDonald, Indulis R. Rutks, Preetham Reddy, Timothy J Wilt · 2011 · Annals of Internal Medicine
7. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials
   Chatree Chai‐Adisaksopha, Christopher Hillis, Tetsuya Isayama, Wendy Lim, Alfonso Iorio, Mark Andrew Crowther · 2015 · Journal of Thrombosis and Haemostasis
8. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management
   Ka Shing Cheung, Wai K. Leung · 2017 · World Journal of Gastroenterology
9. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
   Jessica L. Mega, Joseph R. Walker, Christian Thomas Ruff, Alexander G. Vandell, Francesco Nordio, Naveen Deenadayalu, Sabina A. Murphy, James Lee, Michele F. Mercuri, Robert Patrick Giugliano et al. · 2015 · The Lancet
10. Long-Term Propensity Score–Matched Comparison of Percutaneous Closure of Patent Foramen Ovale With Medical Treatment After Paradoxical Embolism
    Andreas Wahl, Peter Jüni, Marie‐Luise Mono, Bindu Kalesan, Fabien Praz, Laura Geister, Lorenz Räber, Krassen Nedeltchev, Heinrich Paul Mattle, Stephan Windecker et al. · 2012 · Circulation
11. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics
    Sophie Testa, Armando Tripodi, Cristina Legnani, Vittorio Pengo, Rosanna Abbate, Claudia Dellanoce, Paolo Carraro, Luisa Salomone, Rita Paniccia, Oriana Paoletti et al. · 2015 · Thrombosis Research
12. Cardiovascular drug therapy in the elderly: benefits and challenges
    Fleg, Jerome L., Aronow, Wilbert S., Frishman, William H. · 2011 · Nature Reviews Cardiology
13. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN)
    Frans Van de Werf, Martina Brueckmann, Stuart J. Connolly, Jeffrey E. Friedman, Christopher Bull Granger, Sebastian Härtter, Ruth Harper, A. Pieter Kappetein, Thorsten Lehr, Michael J. Mack et al. · 2012 · American Heart Journal
14. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients
    François Laliberté, Michel Cloutier, Winnie W. Nelson, Craig Ian Coleman, Dominic Pilon, William H. Olson, C.V. Damaraju, Jeffrey R Schein, Patrick Lefèbvre · 2014 · Current Medical Research and Opinion
15. Improving Stroke Risk Stratification in Atrial Fibrillation
    Gregory Y.H. Lip, Jonathan L. Halperin · 2010 · The American Journal of Medicine
16. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
    Antonio Gómez‐Outes, Ana Isabel Terleira‐Fernández, Gonzalo Calvo, Ma Luisa Suárez‐Gea, Emilio Vargas · 2013 · Thrombosis
17. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke
    Peter Malcolm Rothwell, Ale Algra, Pierre Amarenco · 2011 · The Lancet
18. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study
    Rikke Sørensen, Gunnar Gislason, Christian Tobias Torp-Pedersen, Jonas Bjerring Olesen, Emil Loldrup Fosbøl, Morten Winther Hvidtfeldt, Deniz Karasoy, Morten Lamberts, Mette Gitz Charlot, Lars Køber et al. · 2013 · BMJ Open
19. New Oral Anticoagulants and the Risk of Intracranial Hemorrhage
    Saurav Chatterjee, Partha Sardar, Giuseppe Biondi‐Zoccai, Dharam J. Kumbhani · 2013 · JAMA Neurology
20. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin
    Matthew William Sherwood, Christopher C. Nessel, Anne S. Hellkamp, Kenneth W. Mahaffey, Jonathan Paul Piccini, Eunyoung Suh, Richard Clinton Becker, Daniel E. Singer, Jonathan L. Halperin, Graeme J. Hankey et al. · 2015 · Journal of the American College of Cardiology
21. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial
    Elvin Kedhi, Enrico Fabris, Martin van der Ent, Paweł Eugeniusz Buszman, Clemens von Birgelen, Vincent Roolvink, Aleksander Żurakowski, Carl E. Schotborgh, Jan C.A. Hoorntje, Christian Hesbø Eek et al. · 2018 · BMJ
22. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban
    Thorsten Steiner, Michael Böhm, Martin Dichgans, HC Diener, Christian Ell, Matthias Endres, Corina Epple, Martin Grond, Ulrich Laufs, Georg Nickenig et al. · 2013 · Clinical Research in Cardiology
23. Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
    Jonas Oldgren, Signild Åsberg, Ziad Hijazi, Per Olov Wester, Maria Bertilsson, Bo G Norrving, for the National TIMING Collaborators · 2022 · Circulation
24. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark
    Kasper Gadsbøll, Laila Stærk, Emil Loldrup Fosbøl, Caroline Sindet‐Pedersen, Anna Gundlund, Gregory Y.H. Lip, Gunnar Gislason, Jonas Bjerring Olesen · 2016 · European Heart Journal
25. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study
    Davis, R. C., Hobbs, F. D. R., Kenkre, J. E., Roalfe, A. K., Iles, R., Lip, G. Y. H., Davies, M. K. · 2012 · Europace
26. Complications arising from catheter ablation of atrial fibrillation: Temporal trends and predictors
    Hana Hoyt, Aditya Bhonsale, Karuna Chilukuri, Fawaz Alhumaid, Matthew Needleman, David Edwards, Ashul Govil, Saman Nazarian, Alan Cheng, Charles A. Henrikson et al. · 2011 · Heart Rhythm
27. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis
    Piérre Siè, Charles Marc Samama, Anne Godiér, Nadia Rosencher, A. Steib, Juan V. Llau, Philippe Van der Linden, Gilles Pernod, Thomas Lecompte, Isabelle Gouin‐Thibault et al. · 2011 · Archives of cardiovascular diseases
28. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants
    Victoria Allan, Sreeram V Ramagopalan, Jack Mardekian, Aaron K. Jenkins, Xiaoyan Li, Xianying Pan, Xuemei Luo · 2020 · Journal of Comparative Effectiveness Research
29. Adherence to oral anticoagulant therapy in patients with atrial fibrillation
    Valeria Raparelli, Marco Proietti, Roberto Cangemi, Gregory Y.H. Lip, Deirdre A. Lane, Stefania Basili · 2016 · Thrombosis and Haemostasis
30. Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial
    Linda P.T. Joosten, Sander van Doorn, Peter M. van de Ven, B T G Kohlen, Melchior C. Nierman, Huiberdina L. Koek, Martin E W Hemels, Menno Volkert Huisman, Marieke J.H.A. Kruip, Laura M. Faber et al. · 2023 · Circulation
31. Secondary stroke prevention: challenges and solutions
    José Gutierrez, Charles C. Esenwa · 2015 · Vascular Health and Risk Management
32. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: An analysis from ASSERT
    Elizabeth S. Kaufman, Carsten Walter Israel, Girish M. Nair, Luciana Armaganijan, Syamkumar Divakaramenon, Georges H. Mairesse, Axel Brandes, Eugene Crystal, Otto Costantini, Roopinder Kaur Sandhu et al. · 2012 · Heart Rhythm
33. Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents
    Ronan Lordan, Αλέξανδρος Τσούπρας, Ioannis Zabetakis · 2020 · Blood Reviews
34. Vascular calcification: The price to pay for anticoagulation therapy with vitamin K-antagonists
    Martijn L. L. Chatrou, Kristien Winckers, Tilman M. Hackeng, Chris P.M. Reutelingsperger, Leon J. Schurgers · 2012 · Blood Reviews
35. Using the CHA2DS2-VASc Score for Refining Stroke Risk Stratification in ‘Low-Risk’ Asian Patients With Atrial Fibrillation
    Tze‐Fan Chao, Chia‐Jen Liu, Kang-Ling Wang, Yenn‐Jiang Lin, Shih‐Lin Chang, Li‐Wei Lo, Yu‐Feng Hu, Ta‐Chuan Tuan, Tzeng‐Ji Chen, Gregory Y.H. Lip et al. · 2014 · Journal of the American College of Cardiology
36. Left Atrial Strain Provides Incremental Value for Embolism Risk Stratification over CHA2DS2-VASc Score and Indicates Prognostic Impact in Patients with Atrial Fibrillation
    Masaru Obokata, Kazuaki Negishi, Koji Kurosawa, Rieko Tateno, Shoichi Tange, Masashi Arai, Masao Amano, Masahiko Kurabayashi · 2014 · Journal of the American Society of Echocardiography
37. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis
    Armando Tripodi, Massimo Primignani, Laura Lemma, Veena Chantarangkul, Pier Mannuccio Mannucci · 2013 · Journal of Hepatology
38. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)
    L. Samüel Wann, Anne B. Curtis, Kenneth A. Ellenbogen, N.A. Mark Estes, Michael D. Ezekowitz, Warren M. Jackman, Craig T. January, James E. Lowe, Richard L. Page, David J. Slotwiner et al. · 2011 · Journal of the American College of Cardiology
39. Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K Antagonists
    Géric Maura, Pierre‐Olivier Blotière, Kim Bouillon, Cécile Billionnet, Philippe Ricordeau, François Alla, Mahmoud Zureik · 2015 · Circulation
40. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation
    Surbhi Shah, Faye L. Norby, Yvonne H. Datta, Pamela L. Lutsey, Richard F. MacLehose, Lin Y. Chen, Álvaro Alonso · 2018 · Blood Advances
41. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Dialysis
    Toshiki Kuno, Hisato Takagi, Tomo Ando, Takehiro Sugiyama, Satoshi Miyashita, Nelson Valentin, Yuichi J. Shimada, Masaki Kodaira, Yohei Numasawa, Αlexandros Briasoulis et al. · 2020 · Journal of the American College of Cardiology
42. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC
    Anja Katholing, Christopher Wallenhorst, Saul Benedict Freedman, Carlos Martínez · 2015 · Thrombosis and Haemostasis
43. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
    Claes Held, Elaine M. Hylek, John Hunter Alexander, M. Hanna, Renato D. Lópes, DANIEL M. WOJDYLA, Laine Elliott Thomas, Hussein R. Al‐Khalidi, Marco Alings, Denis Xavier et al. · 2014 · European Heart Journal
44. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes
    Candrika D. Khairani, Antoine Bejjani, Gregory Piazza, David Jiménez, Manuel Monréal, Saurav Chatterjee, Vittorio Pengo, Scott C. Woller, Josefina Cortés-Hernández, Jean M. Connors et al. · 2022 · Journal of the American College of Cardiology
45. Non-inferiority study design: lessons to be learned from cardiovascular trials
    Stuart J. Head, Sanjay Kaul, Ad J.J.C. Bogers, A. Pieter Kappetein · 2012 · European Heart Journal
46. Effectiveness and Safety of Non–vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses
    Abdulaali R. Almutairi, Lili Zhou, Walid F. Gellad, Jeannie K. Lee, Marion Kimball Slack, Jennifer R Martin, Wei-Hsuan Lo-Ciganic · 2017 · Clinical Therapeutics
47. Haemostasis and innate immunity – a complementary relationship
    Charithani Bhagya Keragala, Dominik F. Draxler, Zoe McQuilten, Robert Lindsay Medcalf · 2017 · British Journal of Haematology
48. Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation
    Michael D. Ezekowitz, Lars C. Wallentin, Stuart J. Connolly, Amit Parekh, Michael Ross Chernick, Janice M. Pogue, Timothy H. Aikens, Sean Yang, Paul A. Reilly, Gregory Y.H. Lip et al. · 2010 · Circulation
49. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents
    Marcel M Levi, Elise S. Eerenberg, Pieter Willem Kamphuisen · 2011 · Journal of Thrombosis and Haemostasis
50. Update in Intracerebral Hemorrhage
    Maria I. Aguilar, Thomas G. Brott · 2011 · The Neurohospitalist
51. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal
    Gregory Y.H. Lip, Marco Proietti, Tatjana Potpara, MOUSSA C. MANSOUR, Irina Savelieva, Hung‐Fat Tse, Andreas Goette, A. John Camm, Carina Blomström‐Lundqvist, Dhiraj Gupta et al. · 2023 · EP Europace
52. Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator
    Ying Xian, Li Liang, Eric Edward Smith, Lee H. Schwamm, Mathew J. Reeves, DaiWai M. Olson, Adrian F. Hernandez, Gregg C. Fonarow, Eric David Peterson · 2012 · JAMA
53. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease
    John W. Stanifer, Sean D. Pokorney, Glenn Matthew Chertow, Stefan Hans Hohnloser, DANIEL M. WOJDYLA, Samira J. Merali, Wonkyung Byon, Ziad Hijazi, Renato D. Lópes, John Hunter Alexander et al. · 2020 · Circulation
54. 2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to play
    Lampert, Rachel, Chung, Eugene H., Ackerman, Michael J., Arroyo, Alonso Rafael, Darden, Douglas, Deo, Rajat, Dolan, Joe, Etheridge, Susan P., Gray, Belinda R., Harmon, Kimberly G. et al. · 2024 · Heart Rhythm
55. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review
    Dorothy M. Adcock, Robert C. Gosselin · 2015 · Thrombosis Research
56. Antithrombotic Therapy in Patients With Chronic Kidney Disease
    Davide Capodanno, Dominick Joseph Angiolillo · 2012 · Circulation
57. Measurement of non‐Coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology
    Steve Kitchen, Elaine Gray, Ian J. Mackie, Trevor P Baglin, Mike Makris · 2014 · British Journal of Haematology
58. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients
    Bob Weijs, Yuri Blaauw, Roger J. M. W. Rennenberg, Leon J. Schurgers, Carl C. Timmermans, Laurent Pison, Robby Nieuwlaat, Leonard Hofstra, Abraham A. Kroon, Joachim Ernst Wildberger et al. · 2011 · European Heart Journal
59. Design of Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate vs. Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source (Re-Spect Esus)
    Hans‐Christoph Diener, J. Donald Easton, Christopher Bull Granger, Lisa Cronin, Christine Duffy, Daniel Cotton, Martina Brueckmann, Ralph L. Sacco · 2015 · International Journal of Stroke
60. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling
    Jan Steffel, Robert Patrick Giugliano, Eugene Braunwald M. D, Sabina A. Murphy, Michele F. Mercuri, Youngsook Choi, Philip E. Aylward, Harvey Douglas White, José Luis Zamorano, Elliott Marshall Antman et al. · 2016 · Journal of the American College of Cardiology
61. Oral bioavailability of dabigatran etexilate ( P radaxa ® ) after co‐medication with verapamil in healthy subjects
    Sebastian Härtter, Regina Sennewald, Gerhard Nehmiz, Paul A. Reilly · 2012 · British Journal of Clinical Pharmacology
62. Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting
    Jerrold H. Levy, David Faraoni, Jenna L. Spring, James Demetrios Douketis, Charles Marc Samama · 2013 · Anesthesiology
63. Acute management of bleeding in patients on novel oral anticoagulants
    Deborah M. Siegal, Mark Andrew Crowther · 2012 · European Heart Journal
64. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation
    Yi‐Hsin Chan, Chi-Tai Kuo, Yung‐Hsin Yeh, Shang‐Hung Chang, Lung‐Sheng Wu, Hsin‐Fu Lee, Hui‐Tzu Tu, Lai‐Chu See · 2016 · Journal of the American College of Cardiology
65. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial
    Chiara Melloni, Allison M. Dunning, Christopher Bull Granger, Laine Elliott Thomas, Michel Georges Khouri, David A. Garcia, Elaine M. Hylek, Michael Hanna, Lars C. Wallentin, Bernard John Gersh et al. · 2017 · The American Journal of Medicine
66. Factors Associated With Thrombotic Complications After the Fontan Procedure
    Brian W. McCrindle, Cedric Manlhiot, Andrew Donald Cochrane, Robin E. Roberts, Marina L. Hughes, Barbara Szechtman, Robert Gideon Weintraub, Maureen E. Andrew, Paul Monagle · 2012 · Journal of the American College of Cardiology
67. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation
    Heyder Omran, Rupert Martin Bauersachs, Siegfried Rübenacker, Franz Goss, Christoph Hammerstingl · 2012 · Thrombosis and Haemostasis
68. What is ‘valvular’ atrial fibrillation? A reappraisal
    Raffaele De Caterina, A. John Camm · 2014 · European Heart Journal
69. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013
    Jonas Bjerring Olesen, Rikke Sørensen, Morten Lock Hansen, Morten Lamberts, Peter Ejvin Weeke, Anders Pretzmann Mikkelsen, Lars Køber, Gunnar Gislason, Christian Tobias Torp-Pedersen, Emil Loldrup Fosbøl · 2014 · EP Europace
70. Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation
    Mohamed Bassiouny, Walid I. Saliba, John Rickard, Mingyuan Shao, Albert Sey, Mariam Diab, David O. Martin, Ayman Ali Hussein, Maurice Khoury, Bernard Abi‐Saleh et al. · 2013 · Circulation Arrhythmia and Electrophysiology
71. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
    Wolfgang Mueck, Stephan Schwers, Jan Julius Stampfuss · 2013 · Thrombosis Journal
72. An update of consensus guidelines for warfarin reversal
    Huyen Anh Tran, Sanjeev Daya Chunilal, Paul L. Harper, Huy Tran, Erica M. Wood, Alexander S. Gallus · 2013 · The Medical Journal of Australia
73. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies
    Apostolos Tzikas, David R. Holmes, Sameer A. Gafoor, Carlos Eduardo Ruiz, Carina Blomström‐Lundqvist, Hans‐Christoph Diener, Riccardo Cappato, Saibal Kar, Randal J. Lee, Robert A. Byrne et al. · 2016 · EuroIntervention
74. Recent strategies in spray drying for the enhanced bioavailability of poorly water-soluble drugs
    Mark T. Davis, Gavin Walker · 2017 · Journal of Controlled Release
75. Social determinants of atrial fibrillation
    Utibe R. Essien, Jelena Kornej, Amber E. Johnson, Lucy Schulson, Emelia J. Benjamin, Jared W. Magnani · 2021 · Nature Reviews Cardiology
76. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study
    Friberg, Leif, Benson, Lina, Lip, Gregory Y.H. · 2015 · European Heart Journal
77. Thromboembolism in Atrial Fibrillation
    Jan Menke, Lars Lüthje, Andreas Kastrup, Jörg Larsen · 2010 · The American Journal of Cardiology
78. Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
    Shinya Goto, Jun Zhu, Lisheng Liu, Byung‐Hee Oh, DANIEL M. WOJDYLA, Philip E. Aylward, Maria Cecilia Bahit, Bernard John Gersh, Michael Hanna, John David Horowitz et al. · 2014 · American Heart Journal
79. The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants
    Meyer Michel Samama · 2010 · Thrombosis Research
80. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
    Michael D. Ezekowitz, Rangadham Nagarakanti, Herbert Noack, Martina Brueckmann, Claire Litherland, Mark Jacobs, Andreas Clemens, Paul A. Reilly, Stuart J. Connolly, Salim Yusuf et al. · 2016 · Circulation
81. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition)
    Samer Narouze, Honorio T. Benzon, David Anthony Provenzano, Asokumar Buvanendran, José Antonio De Andrés, Timothy Ray Deer, Richard L Rauck, Marc Alan Huntoon · 2017 · Regional Anesthesia & Pain Medicine
82. Detection of Previously Undiagnosed Atrial Fibrillation in Patients With Stroke Risk Factors and Usefulness of Continuous Monitoring in Primary Stroke Prevention
    Paul Ziegler, Taya V. Glotzer, Emile G. Daoud, Daniel E. Singer, Michael D. Ezekowitz, ROBERT H. HOYT, Jodi L. Koehler, James A. Coles, D. George Wyse · 2012 · The American Journal of Cardiology
83. Removal of Dabigatran by Hemodialysis
    Don N. Chang, William E. Dager, Andrew I. Chin · 2012 · American Journal of Kidney Diseases
84. Acutely Injured Patients on Dabigatran
    Bryan A. Cotton, James J McCarthy, John Bradley Holcomb · 2011 · New England Journal of Medicine
85. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation
    Victoria Jacobs, Heidi Thomas May, Tami L. Bair, Brian G. Crandall, Michael J. Cutler, John D. Day, Charles D. Mallender, Jeffrey S. Osborn, Scott M. Stevens, J. Peter Weiss et al. · 2016 · The American Journal of Cardiology
86. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis
    Virginie Dufrost, Jessie Risse, Tatiana Magomedalievna Reshetnyak, M. A. Satybaldyeva, Yao Du, Xin-Xin Yan, Stella Salta, Grigoris Gerotziafas, Zhi‐Cheng Jing, Ismaël Elalamy et al. · 2018 · Autoimmunity Reviews
87. Stroke and Thromboembolism in Atrial Fibrillation
    Ron Pisters, Deirdre A. Lane, Francisco R. Marín, A. John Camm, Gregory Y.H. Lip · 2012 · Circulation Journal
88. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation
    Judith S. Hecker, Sandra Marten, Loretta Keller, Sindy Helmert, Franziska Michalski, Sebastian Werth, Kurtuluş Şahin, Luise Tittl, Jan Beyer‐Westendorf · 2016 · Thrombosis and Haemostasis
89. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice
    Xiaoyan Li, Steve Deitelzweig, Allison V. Keshishian, Melissa Hamilton, Ruslan V. Horblyuk, Kiran B. Gupta, Xuemei Luo, Jack Mardekian, Keith E. Friend, Anagha Nadkarni et al. · 2017 · Thrombosis and Haemostasis
90. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study
    Shadi R. Yaghi, Liqi Shu, Ekaterina Bakradze, Setareh Salehi Omran, James A. Giles, Jordan Yardain Amar, Nils Henninger, Marwa Elnazeir, Ava Leigh Liberman, Khadean Moncrieffe et al. · 2022 · Stroke
91. Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning
    Péter Ferdinandy, Ioanna Andreadou, Gary F. Baxter, Hans Erik Bøtker, Sean M. Davidson, Dobromir Dobrev, Bernard John Gersh, Gerd Heusch, Sandrine Lecour, Marisol Ruiz‐Meana et al. · 2022 · Pharmacological Reviews
92. Atrioesophageal Fistula
    Hui‐Chen Han, Francis Jonathan Ha, Prashanthan Sanders, Ryan Spencer, Andrew W. Teh, David O’Donnell, Omar Farouque, Han Sung Lim · 2017 · Circulation Arrhythmia and Electrophysiology
93. Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulants
    Sophie Testa, Oriana Paoletti, Cristina Legnani, Claudia Dellanoce, Emilia Antonucci, Benilde Cosmi, Vittorio Pengo, D. Poli, Rossella Morandini, Roberto Testa et al. · 2018 · Journal of Thrombosis and Haemostasis
94. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study
    Di Biase, Luigi, Lakkireddy, Dhanujaya, Trivedi, Chintan, Deneke, Thomas, Martinek, Martin, Mohanty, Sanghamitra, Mohanty, Prasant, Prakash, Sameer, Bai, Rong, Reddy, Madhu et al. · 2015 · Heart Rhythm
95. Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.
    Luciano Crippa, Anna Falanga, Guido Finazzi, Francesco Marongiu, Gualtiero Palareti, Daniela Poli, Sophie Testa, Eros Tiraferri, Alberto Tosetto, Armando Tripodi et al. · 2011 · Thrombosis and Haemostasis
96. Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries
    Harriette G.C. Van Spall, Lars C. Wallentin, Salim Yusuf, John W. Eikelboom, Robby Nieuwlaat, Sean Yang, Conrad Kabali, Paul A. Reilly, Michael D. Ezekowitz, Stuart J. Connolly · 2012 · Circulation
97. Effectiveness and Safety of Dabigatran and Warfarin in Real‐World US Patients With Non‐Valvular Atrial Fibrillation: A Retrospective Cohort Study
    Julie C. Lauffenburger, Joel F. Farley, Anil K. Gehi, Denise H. Rhoney, M. Alan Brookhart, Gang Fang · 2015 · Journal of the American Heart Association
98. Implications of the CHA2DS2-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial Fibrillation
    Gregory Y.H. Lip · 2010 · The American Journal of Medicine
99. Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II
    Essien, Utibe R., Holmes, DaJuanicia N., Jackson, Larry R., Fonarow, Gregg C., Mahaffey, Kenneth W., Reiffel, James A., Steinberg, Benjamin A., Allen, Larry A., Chan, Paul S., Freeman, James V. et al. · 2018 · JAMA Cardiology
100. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial
     Kirchhof, Paulus, Breithardt, Günter, Camm, A. John, Crijns, Harry J., Kuck, Karl-Heinz, Vardas, Panos, Wegscheider, Karl · 2013 · American Heart Journal